Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
High levels of life sciences mergers and acquisitions in the tail-end of 2013 may make for a busy start to 2014, according to a report from PricewaterhouseCoopers.
Medtech M&A contracted overall last year, with the 41 reported deals representing a 13% drop since 2012, but the end of the year saw a surge in activity in the overall life sciences sector. Deals announced late last year and those that had not closed as of the end of the 4th quarter could help jump-start 2014 and may signal a healthy turn for the industry. Read more
Federal healthcare regulators put their highest-risk Class I label on a new warning issued over GE Healthcare’s (NYSE:GE) Giraffe and Panda neonatal infant warmers and resuscitation systems.
The devices, originally recalled in October 2013, have components that were installed backwards during assembly. The error may result in devices delivering inaccurate levels of oxygen and may lead to over- or under-oxygenation that could cause infants injury or even death, FDA warned. Read more
Respiratory Motion is on a roll, landing nearly $6 million in new funding and unveiling positive results from a clinical study of its ExSpiron non-invasive respiratory monitor.
The Waltham, Mass.-based hopes to close the Series B round with $8.8 million, having raised $5.8 million so far from lead investor Easton Capital and other existing investors. The funds are slated to support sales and marketing efforts for the ExSpiron system, the company said. Read more